In:
Journal of Diabetes Investigation, Wiley, Vol. 9, No. 2 ( 2018-03), p. 274-278
Abstract:
The aim of the present study was to evaluate the properties of the glucagon stimulation test ( GST ) and the normal meal tolerance test ( NMTT ) in patients with type 2 diabetes. Materials and Methods We enrolled 142 patients with type 2 diabetes, and carried out a GST and a NMTT . We carried out the NMTT using a calorie‐controlled meal based on an intake of 30 kcal/kg ideal bodyweight/day. We calculated the change in C‐peptide immunoreactivity (Δ CPR ) by subtracting fasting CPR from the CPR 6 min after the 1‐mg glucagon injection ( GST ) or 120 min after the meal ( NMTT ). Results Mean Δ CPR for the GST was 2.0 ng/ mL , and for the NMTT was 3.1 ng/ mL . A total of 104 patients had greater Δ CPR in the NMTT than the GST , and the mean Δ CPR was significantly greater in the NMTT than the GST ( P 〈 0.05). To exclude any influence of antidiabetic drugs, we examined 42 individuals not taking antidiabetic agents, and found the mean Δ CPR was significantly greater in the NMTT than the GST ( GST 2.4 ng/ mL , NMTT 4.3 ng/ mL ; P 〈 0.05). To consider the influence of glucose toxicity, we carried out receiver operating characteristic analyses with fasting plasma glucose and glycated hemoglobin. The optimal cut‐off levels predicting GST Δ CPR to be larger than NMTT Δ CPR were fasting plasma glucose 147 mg/ dL and glycated hemoglobin 9.0% (fasting plasma glucose: sensitivity 0.64, specificity 0.76, area under the curve 0.73; glycated hemoglobin: sensitivity 0.56, specificity 0.71, area under the curve 0.66). Conclusions The NMTT is a reliable insulin secretion test in patients with type 2 diabetes, except for those in a hyperglycemic state.
Type of Medium:
Online Resource
ISSN:
2040-1116
,
2040-1124
DOI:
10.1111/jdi.2018.9.issue-2
Language:
English
Publisher:
Wiley
Publication Date:
2018
detail.hit.zdb_id:
2625840-7
detail.hit.zdb_id:
2542077-X
Permalink